Nearly 80% of the residues of c-MYC that interacts with USP37 have been found interacting with the designed peptide, suggesting that the peptide is specific to c-MYC-USP37 complex and could be used for targeted therapy against the ABC subtype of DLBCL. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.